Neoplasm Metastases Clinical Trial
Official title:
Phase I Study of mTOR Inhibitor RAD001 in Combination With IGF-1R Inhibitor AMG479 for Patients With Advanced Solid Tumors
The purpose of this study is to test the safety of the combination of two drugs called RAD001 and AMG479. This study will see what effects (good and bad) RAD001 and AMG479 have on cancer. This study will also find the highest doses of RAD001 and AMG479 that can be given without causing severe side effects.
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated (MTD) and recommended Phase II doses for AMG479
(ganitumab) and RAD001 (everolimus) in patients with refractory solid tumors.
II. To determine the safety and toxicity of AMG479 and RAD001.
SECONDARY OBJECTIVES:
I. To determine preliminary antitumor efficacy of AMG479 and RAD001 in solid tumors:
response and stable disease rates, duration of response and of stable disease, time to
progression (TTP) and overall survival (OS).
II. For all patients, to analyze tumor and blood samples for pharmacodynamic biomarkers
related to IGF-1R and mTOR signaling: pAkt, pS6, p-4EBP1, PTEN, IGF-1, IGF-2, pIGF-1R and
IGFBP3 and correlate with response and stable disease.
III. For all patients, to analyze the pharmacokinetic profile (PK) for RAD001 and AMG479,
and correlate with response/stable disease and pharmacodynamic markers.
IV. To evaluate the effects of RAD001 on AMG 479 pharmacokinetics.
OUTLINE: This is a dose-escalation study.
Patients receive everolimus orally (PO) once daily (QD) on days 1-28 (days 1-7 and 16-28 of
course 1 only) and ganitumab intravenously (IV) over 60 minutes on days 1 and 15 (day 15 of
course 1 only). Courses repeat every 28 days in the absence of disease progression or
unacceptable toxicity.
After completion of study treatment, patients are followed up at day 30, every 3 months for
2 years from registration for study treatment, every 6 months for years 3-5, and then
annually thereafter.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03911388 -
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
|
Phase 1 | |
| Completed |
NCT02953756 -
Cognitive Outcome After Gamma Knife Radiosurgery in Patients With Brain Metastases (CAR-Study A)
|
||
| Terminated |
NCT02565433 -
Prospective Assessment of Quality of Life in Patients Treated by Radiosurgery for Brain Metastases (PRAMECE-1302)
|
N/A | |
| Completed |
NCT00184353 -
Clinical MR Spectroscopy of Brain Metastases at 1,5T and 3T.
|
N/A | |
| Recruiting |
NCT02789371 -
Comparing of Modified Wet Suction Technique and Dry Suction Technique for EUS-FNA of Solid Occupying Lesions
|
N/A | |
| Terminated |
NCT01336985 -
Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads
|
Phase 1 | |
| Recruiting |
NCT05419518 -
Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas
|
Phase 2 | |
| Completed |
NCT02808416 -
Personalized Cellular Vaccine for Brain Metastases (PERCELLVAC3)
|
Phase 1 | |
| Completed |
NCT00668382 -
Evaluate The Toxicity And Feasibility Of Intra-Tumoral Injection
|
Phase 1 | |
| Completed |
NCT00152906 -
Stereotactic Radiotherapy (SRT) Liver (COLD 1)
|
Phase 1/Phase 2 | |
| Completed |
NCT01267084 -
A Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02327065 -
Prospective Multi-center, Single Blinded, Randomized, Controlled Trial of EUS-FNB and EUS-FNA on Solid Occupying Lesion
|
N/A | |
| Completed |
NCT02382653 -
Oral Piroxicam Versus Buccal Fentanyl in Breakthrough Pain
|
N/A | |
| Completed |
NCT01273493 -
A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
|
Phase 1 | |
| Completed |
NCT01273480 -
A Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT00556049 -
Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT02246634 -
Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE)
|
N/A | |
| Terminated |
NCT01970644 -
Neurocognition After Gamma Knife Radiosurgery for Multiple Brian Metastases
|
N/A |